

Sheppard Mullin Advises TP ICAP, CREATD, ADITZ Therapeutics And Others In Recent Deals

10.20.2020

Sheppard Mullin's Corporate practice has been busy closing a variety of deals and transactions recently:

- Represented **Kiromic Biopharma** in the closing of its \$15 million initial public offering. Kiromic is a target discovery and gene-editing company utilizing artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology. The shares began trading on the Nasdaq Capital Market on October 16, 2020 under the ticker symbol "KRBP". The Sheppard Mullin team included partner Jeff Fessler and associate Justin Anslow. (October 20)
- Advised **Ladenburg Thalmann & Co Inc.** as placement agent in connection with a \$5.1 million registered direct offering of common stock and warrants of Hancock Jaffe Laboratories, Inc., a developer and manufacturer of bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases. The Firm also advised Ladenburg Thalmann & Co in connection with a \$7 million at-the-market offering of common stock of Jaguar Health, Inc., a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. The Sheppard Mullin team was led by partner Richard Friedman and associate Justin Anslow. (October 9)
- Advised **Cardiff Oncology, Inc.**, a clinical-stage oncology therapeutics company, on its \$100 million (with over-allotment) follow-on public offering. The Sheppard Mullin team was led by partner Jeff Fessler and associate Justin Anslow with special assistance from partner Jing Liu and associate Paul Chang. (October 2)
- Represented **Amesite, Inc.** with the closing of its \$15 million initial public offering. Amesite is a high-tech artificial intelligence software company offering a cloud-based platform and content creation services for K-12, college, university and business education and upskilling. The Sheppard Mullin team included partner Richard Friedman and associates Alexander Yarbrough and Seth Lemings. (September 29)
- Represented **Creatd, Inc.** (formerly Jerrick Media Holdings, Inc.) in connection with its \$7.7 million underwritten public offering. Creatd is the parent company and creator of the Vocal platform, which empowers content creators and brands through technology and data-driven innovation. The Sheppard Mullin deal team included partner Richard Friedman and associate Alex Yarbrough. (September 15)
- Advised **Aditx Therapeutics, Inc.** (Nasdaq: ADTX) in its previously announced upsized \$9.6 million underwritten public offering. Sheppard Mullin also advised Aditx on its initial IPO in July. Aditx develops technologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring. The Sheppard Mullin deal team was led by partner Richard Friedman and included associates Alex Yarbrough and Taylor Ashton. (September 10)
- Advised the joint bookrunning managers, **The Benchmark Company, LLC and Axiom Capital Management, LLC**, in connection with a \$6 million secondary public offering of Common Stock of Senmiao Technology

Limited, a provider of automobile transaction services. The Sheppard Mullin team included partner Richard Friedman and associates Alex Yarbrough, Justin Anslow and Yuanmei Lu. (August 6)

- Represented **TP ICAP plc**, a global firm of professional intermediaries that plays a pivotal role in the world's financial, energy and commodities markets, in its acquisition of Louis Capital Markets and MidCap Partners (collectively "Louis Capital"), a private brokerage group specializing in equities and fixed income, primarily based in Europe. The Sheppard Mullin deal team was led by partner Luca Salvi and included partners Jeff Kern, Keith Gercken and Carlo Van den Bosch, special counsel Malika Levarlet and Verity Rees and associate Felicia Xu. (July 31)

Attorneys

Jeffrey J. Fessler

Richard A. Friedman

Keith R. Gercken

Jeff Kern

Seth A. Lemings

Malika Levarlet

Yuanmei Lu

Carlo F. Van den Bosch

Practice Areas

Capital Markets

Corporate

Healthcare

Intellectual Property

Mergers and Acquisitions

Technology Transactions

Industries

Healthcare

Life Sciences